The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: The evaluation of Exubera® as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial

Diabetic Medicine

Volumn 25, Issue 6, 2008, Pages 662-670

  Del Prato, S ^a   Blonde, L ^b   Martinez, L ^c   Goke B ^d   Woo, V ^e   Millward, A ^f   Gomis, R ^g   Canovatchel, B ^h   Strack, T ^h   Lawrence, D ^h   Freemantle, N ⁱ  

^a UNIVERSITY OF PISA   (Italy)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c Societe Francaise de Medecine Generale   (France)

^d UNIVERSITY OF MUNICH   (Germany)

^e HEALTH SCIENCES CENTRE   (Canada)

^f PENINSULA MEDICAL SCHOOL   (United Kingdom)

^g UNIVERSITY OF BARCELONA   (Spain)

^h PFIZER INC   (United States)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Glycaemic control; Inhaled insulin; Insulin initiation; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLINIDE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; METFORMIN; RECOMBINANT HUMAN INSULIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DIET THERAPY; DISEASE CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFECTION; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADMINISTRATION, INHALATION; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION ROUTES; EUROPE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NORTH AMERICA; TREATMENT OUTCOME;

EID: 44649181040     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02438.x     Document Type: Article

References (24)

1. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006 23 : 579 593.
2. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al Professional Practice Committee, American Diabetes Associations; European Association for the Study of Diabetes. Management of hyperglycaemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006 49 : 1711 1721.
3. Davidson JA, Blonde L, Jellinger PS, Lebovitz HE, Parkin CG. Road map for the prevention and treatment of Type 2 diabetes. ACE/AACE Diabetes Road Map Task Force. Available at http://www.aace.com/meetings/consensus/ odimplementation/roadmap.pdf Last accessed 26 March 2008.
4. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B Global Partnership for Effective Diabetes Management. Improving glucose management: ten steps to get more patients with Type 2 diabetes to glycaemic goal. Int J Clin Pract 2005 59 : 1345 1355.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
6. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in Type 2 diabetic patients. Diabetes Care 2000 23 : B21 B29.
7. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005 28 : 600 606.
8. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR et al The International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005 28 : 2673 2679.
9. Quattrin TA, Belanger A, Bohannon JHV, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 1 diabetes. Diabetes Care 2004 27 : 2622 2627.
10. Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE et al. Use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005 28 : 1630 1635.
11. Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W Inhaled Human Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with Type 1 diabetes. Diabetes Care 2007 30 : 579 585.
12. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004 27 : 2356 2362.
13. Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with Type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006 29 : 1282 1287.
14. Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in Type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005 143 : 549 558.
15. Freemantle N, Blonde L, Bolinder B, Gerber RA, Hobbs FD, Martinez L et al. Real-world trials to answer real-world questions. Pharmacoeconomics 2005 23 : 747 754.
16. Freemantle N, Strack T the Real World Trialists. Will availability of inhaled human insulin (Exubera(R)) improve management of Type 2 diabetes? The design of the Real World trial. Trials 2006 7 : 25.
17. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FD et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with Type 2 diabetes. Diabetes Care 2005 28 : 427 428.
18. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with Type 2 diabetes: a preliminary report. Diabetes Care 2004 27 : 17 20.
19. Polonsky WH, Jackson RA. What's so tough about taking insulin? Addressing the psychological problem of insulin resistance in Type 2 diabetes. Clin Diabetes 2004 22 : 147 150.
20. Grant RW, Wexler DJ, Watson AJ, Lester WT, Cagliero E, Campbell EG et al. How doctors choose medications to treat Type 2 diabetes: a national survey of specialists and academic generalists. Diabetes Care 2007 30 : 1448 1453.
21. King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M et al. Impact of participation and physician intervention preferences on randomized trials: a systematic review. J Am Med Assoc 2005 293 : 1089 1099.
22. Bastyr EJ 3rd., Johnson ME, Trautmann ME, Anderson JH Jr, Vignati L. Insulin lispro in the treatment of patients with Type 2 diabetes mellitus after oral agent failure. Clin Ther 1999 21 : 1703 1714.
23. Altuntas Y, Ozen B, Oxturk B, Sengul A, Ucak S, Ersoy O et al. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes Obes Metab 2003 5 : 371 378.
24. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998 82 : 67U 73U.